Irritable Bowel Syndrome Treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed IBS (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-10-06
- Report ID: 1385
- Pages: 250
-
Format:
The irritable bowel syndrome treatment market was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026.
Irritable bowel syndrome is a gastrointestinal disorder of gut that may be identified by colon muscle contraction. It majorly affects the large intestine. In addition, it is associated with the malfunction of the bowel, and majorly occurs in geriatric population. Diarrhea, constipation, alteration & discomfort in bowel function, bloating, and abdominal pain are some of the common symptoms of irritable bowel syndrome. Endoscopy and blood test are normally performed to detect this irritable bowel syndrome. Irritable bowel syndrome is classified into three types such as IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS. Treatment of irritable bowel syndrome include proper medicines, change in diet, stress relief, and counseling. Medicines used in the treatment of irritable bowel syndrome include rifaximin, eluxadoline, lubiprostone, linaclotide, and others.
Significant increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, abdominal pain, adoption of sedentary lifestyle, increase in level of stress, and unhealthy diet are the key factors that fuel the growth of the irritable bowel syndrome treatment market. According to the International Foundation for Gastrointestinal Disorders (IFFGD), it was estimated that irritable bowel syndrome affects around 25-45 million in the U.S. in 2016. Moreover, company developing products with symptom specific application and subsequent launches, increase in geriatric population, and rise in awareness programs for irritable bowel syndrome treatment are other factors that contribute toward the growth of the market. Furthermore, rise in prevalence of irritable bowel syndrome in female is expected to further boost the growth of global irritable bowel treatment market during the forecast period. However, high competition among the key players related to pricing and lack of specific treatment which treat all the symptoms of this disorder are expected to hinder the growth of the market.
The irritable bowel syndrome treatment market is segmented into type, product, end user, and region. Depending on type, the market is categorized into IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and Mixed IBS. On the basis of product, the market is classified into rifaximin, eluxadoline, lubiprostone, linaclotide, and others. On the basis of end user, the market is divided into hospitals pharmacies, drug stores & retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Type
IBS with Diarrhea (IBS-D)
IBS with Constipation (IBS-C)
Mixed IBS
By Product
Rifaximin
Eluxadoline
Lubiprostone
Linaclotide
Others
By End User
Hospitals Pharmacies
Drug Stores & Retail Pharmacies
Online Pharmacies
By Region
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Abbott Laboratories
Allergan plc
Ardelyx Inc.
Astellas Pharma Inc.
AstraZeneca plc
GlaxoSmithKline Plc
Johnson & Johnson (McNeil Consumer Healthcare)
Novartis AG
Sebela Pharmaceuticals Inc.
Takeda Pharmaceutical Company Ltd.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Bausch Health
Synthetic Biologics, Inc.
Callisto Pharmaceuticals, Inc. (Synergy Pharmaceuticals)
Ironwood Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc.
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.3. PorterS Five Force Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rise In Geriatric Population
3.4.1.2. Rise In Prevalence of Gastrointestinal Disorders
3.4.1.3. Increase In Number of Pipeline Drugs
3.4.2. Restrains
3.4.2.1. Poor Demand In Under Developed Countries
3.4.3. Opportunities
3.4.3.1. Untapped Opportunities In Developing Economies
3.4.4. Impact Analysis
Chapter 4: Irritable Bowel Syndrome Treatment Market, By Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Ibs With Diarrhea (Ibs-D)
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast
4.2.3. Market Analysis, By Country
4.3. Ibs With Constipation (Ibs-C)
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis, By Country
4.4. Mixed-Presentation Ibs (Ibs-M)
4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast
4.4.3. Market Analysis, By Country
Chapter 5: Irritable Bowel Syndrome Treatment Market, By Product
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Rifaximin
5.2.1. Market Size And Forecast
5.2.2. Market Analysis, By Country
5.3. Eluxadoline
5.3.1. Market Size And Forecast
5.3.2. Market Analysis, By Country
5.4. Lubiprostone
5.4.1. Market Size And Forecast
5.4.2. Market Analysis, By Country
5.5. Linaclotide
5.5.1. Market Size And Forecast
5.5.2. Market Analysis, By Country
5.6. Others
5.6.1. Market Size And Forecast
5.6.2. Market Analysis, By Country
Chapter 6: Irritable Bowel Syndrome Treatment Market, By End User
6.1. Overview
6.1.1. Market Size And Forecast
6.2. Hospitals Pharmacies
6.2.1. Market Size And Forecast
6.2.2. Market Analysis, By Country
6.3. Drug Stores And Retail Pharmacies
6.3.1. Market Size And Forecast
6.3.2. Market Analysis, By Country
6.4. Online Pharmacies
6.4.1. Market Size And Forecast
6.4.2. Market Analysis, By Country
Chapter 7: Irritable Bowel Syndrome Treatment Market, By Region
7.1. Overview
7.1.1. Market Size And Forecast
7.2. North America
7.2.1. Key Market Trends, Growth Factors, And Opportunities
7.2.2. Market Size And Forecast, By Country
7.2.2.1. U.S.
7.2.2.1.1. U.S. Irritable Bowel Syndrome Treatment Market, By Type
7.2.2.1.2. U.S. Irritable Bowel Syndrome Treatment Market, By Product
7.2.2.1.3. U.S. Irritable Bowel Syndrome Treatment Market, By End User
7.2.2.2. Canada
7.2.2.2.1. Canada Irritable Bowel Syndrome Treatment Market, By Type
7.2.2.2.2. Canada Irritable Bowel Syndrome Treatment Market, By Product
7.2.2.2.3. Canada Irritable Bowel Syndrome Treatment Market, By End User
7.2.2.3. Mexico
7.2.2.3.1. Mexico Irritable Bowel Syndrome Treatment Market, By Type
7.2.2.3.2. Mexico Irritable Bowel Syndrome Treatment Market, By Product
7.2.2.3.3. Mexico Irritable Bowel Syndrome Treatment Market, By End User
7.2.3. North America Market Size And Forecast, By Type
7.2.4. North America Market Size And Forecast, By Product
7.2.5. North America Market Size And Forecast, By End User
7.3. Europe
7.3.1. Key Market Trends, Growth Factors, And Opportunities
7.3.2. Market Size And Forecast, By Country
7.3.2.1. Germany
7.3.2.1.1. Germany Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.1.2. Germany Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.1.3. Germany Irritable Bowel Syndrome Treatment Market, By End User
7.3.2.2. France
7.3.2.2.1. France Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.2.2. France Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.2.3. France Irritable Bowel Syndrome Treatment Market, By End User
7.3.2.3. Uk
7.3.2.3.1. Uk Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.3.2. Uk Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.3.3. Uk Irritable Bowel Syndrome Treatment Market, By End User
7.3.2.4. Italy
7.3.2.4.1. Italy Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.4.2. Italy Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.4.3. Italy Irritable Bowel Syndrome Treatment Market, By End User
7.3.2.5. Spain
7.3.2.5.1. Spain Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.5.2. Spain Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.5.3. Spain Irritable Bowel Syndrome Treatment Market, By End User
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe Irritable Bowel Syndrome Treatment Market, By Type
7.3.2.6.2. Rest of Europe Irritable Bowel Syndrome Treatment Market, By Product
7.3.2.6.3. Rest of Europe Irritable Bowel Syndrome Treatment Market, By End User
7.3.3. Europe Market Size And Forecast, By Type
7.3.4. Europe Market Size And Forecast, By Product
7.3.5. Europe Market Size And Forecast, By End User
7.4. Asia-Pacific
7.4.1. Key Market Trends, Growth Factors, And Opportunities
7.4.2. Market Size And Forecast, By Country
7.4.2.1. Japan
7.4.2.1.1. Japan Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.1.2. Japan Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.1.3. Japan Irritable Bowel Syndrome Treatment Market, By End User
7.4.2.2. China
7.4.2.2.1. China Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.2.2. China Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.2.3. China Irritable Bowel Syndrome Treatment Market, By End User
7.4.2.3. Australia
7.4.2.3.1. Australia Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.3.2. Australia Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.3.3. Australia Irritable Bowel Syndrome Treatment Market, By End User
7.4.2.4. India
7.4.2.4.1. India Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.4.2. India Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.4.3. India Irritable Bowel Syndrome Treatment Market, By End User
7.4.2.5. South Korea
7.4.2.5.1. South Korea Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.5.2. South Korea Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.5.3. South Korea Irritable Bowel Syndrome Treatment Market, By End User
7.4.2.6. Rest of Asia-Pacific
7.4.2.6.1. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Type
7.4.2.6.2. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By Product
7.4.2.6.3. Rest of Asia-Pacific Irritable Bowel Syndrome Treatment Market, By End User
7.4.3. Asia-Pacific Market Size And Forecast, By Type
7.4.4. Asia-Pacific Market Size And Forecast, By Product
7.4.5. Asia-Pacific Market Size And Forecast, By End User
7.5. Lamea
7.5.1. Key Market Trends, Growth Factors, And Opportunities
7.5.2. Market Size And Forecast, By Country
7.5.2.1. Brazil
7.5.2.1.1. Brazil Irritable Bowel Syndrome Treatment Market, By Type
7.5.2.1.2. Brazil Irritable Bowel Syndrome Treatment Market, By Product
7.5.2.1.3. Brazil Irritable Bowel Syndrome Treatment Market, By End User
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By Type
7.5.2.2.2. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By Product
7.5.2.2.3. Saudi Arabia Irritable Bowel Syndrome Treatment Market, By End User
7.5.2.3. South Africa
7.5.2.3.1. South Africa Irritable Bowel Syndrome Treatment Market, By Type
7.5.2.3.2. South Africa Irritable Bowel Syndrome Treatment Market, By Product
7.5.2.3.3. South Africa Irritable Bowel Syndrome Treatment Market, By End User
7.5.2.4. Rest of Lamea
7.5.2.4.1. Rest of Lamea Irritable Bowel Syndrome Treatment Market, By Type
7.5.2.4.2. Rest of Lamea Irritable Bowel Syndrome Treatment Market, By Product
7.5.2.4.3. Rest of Lamea Irritable Bowel Syndrome Treatment Market, By End User
7.5.3. Lamea Market Size And Forecast, By Type
7.5.4. Lamea Market Size And Forecast, By Product
7.5.5. Lamea Market Size And Forecast, By End User
Chapter 8: Company Profiles
8.1. Abbott Laboratories
8.1.1. Company Overview
8.1.2. Company Snapshot
8.1.3. Operating Business Segments
8.1.4. Product Portfolio
8.1.5. Business Performance
8.2. Allergan Plc
8.2.1. Company Overview
8.2.2. Company Snapshot
8.2.3. Operating Business Segments
8.2.4. Product Portfolio
8.2.5. Business Performance
8.2.6. Key Strategic Moves And Developments
8.3. Ardelyx Inc.
8.3.1. Company Overview
8.3.2. Company Snapshot
8.3.3. Operating Business Segments
8.3.4. Product Portfolio
8.3.5. Business Performance
8.3.6. Key Strategic Moves And Developments
8.4. Astellas Pharma Inc.
8.4.1. Company Overview
8.4.2. Company Snapshot
8.4.3. Operating Business Segments
8.4.4. Product Portfolio
8.4.5. Business Performance
8.4.6. Key Strategic Moves And Developments
8.5. Astrazeneca Plc
8.5.1. Company Overview
8.5.2. Company Snapshot
8.5.3. Operating Business Segments
8.5.4. Product Portfolio
8.5.5. Business Performance
8.5.6. Key Strategic Moves And Developments
8.6. Glaxosmithkline Plc
8.6.1. Company Overview
8.6.2. Company Snapshot
8.6.3. Operating Business Segments
8.6.4. Product Portfolio
8.6.5. Business Performance
8.7. Johnson & Johnson (Mcneil Consumer Healthcare)
8.7.1. Company Overview
8.7.2. Company Snapshot
8.7.3. Operating Business Segments
8.7.4. Product Portfolio
8.7.5. Business Performance
8.8. Novartis Ag
8.8.1. Company Overview
8.8.2. Company Snapshot
8.8.3. Operating Business Segments
8.8.4. Product Portfolio
8.8.5. Business Performance
8.8.6. Key Strategic Moves And Developments
8.9. Sebela Pharmaceuticals Inc.
8.9.1. Company Overview
8.9.2. Company Snapshot
8.9.3. Operating Business Segments
8.9.4. Product Portfolio
8.10. Takeda Pharmaceutical Company Ltd.
8.10.1. Company Overview
8.10.2. Company Snapshot
8.10.3. Operating Business Segments
8.10.4. Product Portfolio
8.10.5. Business Performance
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
